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1. Introduction 
Glioma is one of the most common primary brain tumors accounting for 30 to 40% of all 
intracranial tumors.  Gliomas can be divided into two types based upon histopathalogic 
diagnosis according to the World Health Organization (WHO) classification, low grade 
(WHO I and II) and high grade (WHO III and IV).  High grade malignant glioblastoma 
accounts for the majority of diagnoses and carries the worst prognosis. Prognosis with 
glioma depends on the patient’s age and Karnofsky performance score (KPS) as well as the 
histological grade of the tumor. For the United States in 2010 there were 6.8 new cases of 
glioblastoma for every 100,000 people1. The current standard of care for patients with newly 
diagnosed high-grade glioma is surgical resection followed by fractionated external beam 
radiation therapy and systemic chemotherapeutic treatment mostly with temozolomide2. 
The single best therapeutic option in the treatment of glioma is extensive surgical resection, 
and the extent of resection directly correlates with the greatest survival benefit. Despite our 
best efforts however, the outcomes for malignant glioblastoma are still very poor with less 
than 5% of patients surviving five years post diagnosis even with the best current 
treatment3. In light of these poor results there is significant room for innovation and 
improvement in the area of surgical management particularly with an objective to increase 
the extent of surgical resection. Throughout this chapter we will discuss the importance of 
surgical resection in the treatment of glioma as well as emerging innovative surgical 
methods and technologies for increasing the extent of resection and improving upon the 
associated survival benefit. We will also explore adjuvant therapies in glioma management 
and the important role that surgery plays in maximizing the potential benefit of these 
adjuvant therapies. 
2. Current surgical management of glioma 
Three options are available for the surgical management of gliomas. The first option is to 
refrain from surgery for as long as possible, sometimes referred to as the “wait and see” 
approach. The second option involves biopsy of the lesion or subtotal resection of surgically 
accessible areas within the tumor in order to obtain histopathology diagnosis. Biopsy and 
subtotal resection are often followed by adjuvant therapies (radiation or chemotherapy). The 
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best surgical option is gross total resection (GTR), usually defined as removal of all areas of 
contrast enhancement on T1 weighted MRI obtained postoperatively. GTR provides the best 
surgical treatment and is associated with the best survival rates; however, it also carries the 
greatest risks of postoperative neurologic deficits and disability. 
Current treatment for glioma, particularly high grade lesions, is not curative and the 
majority of patients experience reoccurrence following initial resection.  Reoccurrence is due 
to the infiltrative nature of these lesions and the inability of current treatment modalities to 
fully remove and destroy all tumor cells. The rationale behind surgical management of these 
aggressive lesions is based on the Gompertzian phenomenon. In 1825, the English 
mathematician Benjamin Gompertz postulated that the biological growth of normal organs 
and malignancies follows a characteristic curve and that cell number increases with time, 
but the relative rate of increase falls exponentially as the mass reaches a “plateau phase” of a 
very slow actual growth4.  Therapy can induce regression in tumor volume, however, there 
is always regrowth between cycles of treatment and this “regrowth” will follow the same 
Gompertzian growth curve.  The only escape from Gompertzian phenomenon is complete 
tumor cell eradication.  Therefore, the ultimate goal of surgical therapy in these tumors should 
be the complete eradication of all abnormal neoplastic cells. With the currently available 
surgical techniques we are still unable to fully resect most of these tumors.  Therefore we need 
new techniques to improve surgical resection as well as adjuvant therapies to eradicate 
remaining tumor cells and thereby maximize the survival benefit of surgery. 
Low grade gliomas (WHO I and II) are a broad group of tumors that are clinically, 
histologically and molecularly diverse. WHO grade I tumors comprise the group of pilocytic 
astrocytoma and subependymal giant cell astrocytoma the more common being pilocytic. 
Management of WHO grade I glioma consists of gross total resection as the treatment of 
choice and carries an excellent prognosis. Following resection, 25-year survival rates of 50-
94% have been reported5.   Grade I lesions are the only glioma subtype where gross total 
resection is considered curative. 
WHO grade II gliomas consist of diffuse fibrillary astrocytoma, oligodendrogliomas, and 
oligoastrocytomas, all of which have similar invasive and malignant potential. Grade II 
gliomas that are symptomatic and surgically accessible should undergo maximal 
cytoreductive surgery as the treatment of choice. Predictors of incomplete tumor resection in 
low grade lesions include tumor involvement of the cortico-spinal tract, large tumor volume, 
and oligodendroglioma histopathologic type. 5 year survival of up to 95-97% has been 
reported following gross total resection in these lesions6. In 2008, Smith and colleagues 
reported a large series of 216 patients with biologically aggressive grade II lesions and 
examined the extent of resection and the effect on overall survival7. Patients with at least 90% 
resection showed 5 and 8 year survivals of 97% and 91% respectively compared to those with 
less than 90% resection who showed survival rates of 76% and 60% at 5 and 8 years.  
For both grade I and grade II tumors, maximal surgical resection is the single best treatment 
for obtaining increased survival.  In cases where there is progressive tumor growth 
following resection or progressive neurological symptoms in unresectable tumors, adjuvant 
chemotherapy or radiation treatment may be used.  
High grade glioma’s (WHO III and IV) consist of anaplastic astrocytoma (Grade III), and 
glioblastoma (Grade IV). These tumors are malignant and carry a significantly poorer 
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prognosis than the low grade lesions. The first line therapy for high-grade glioma is 
cytoreductive surgery with the goal of removing as much abnormal tissue as possible 
without causing further damage to normal parenchyma. The reduction in tumor volume 
results in improved survival and quality of life by delaying recurrence and malignant 
progression. 
There are many studies over the past two decades that examine the extent of cytoreductive 
surgery; gross total resection verses biopsy and subtotal resection in regards to increasing 
patient survival. Tumor location as well as extent of neurologic deficits plays a large role in 
the decision making process for surgical management. One retrospective study in 1996 
showed significant increased mean survival time of 292 days vs 184 days between a group 
undergoing cytoreductive surgery and a group undergoing stereotactic biopsy respectively8. 
However quality of life measured by KPS was not significantly different between the two 
groups.  
A prospective study utilizing 60 patients, examined the extent of resection compared to 
survival. These authors found median survival of 64 weeks for the group who underwent 
gross total resection compared to 36 weeks for the group undergoing subtotal resection9. 
They concluded that patients undergoing subtotal resection have 6.6 times higher risk of 
death.  Another large prospective of study 645 patients showed that patients undergoing 
total resection had a median survival of 11.3 months compared to 10.4 months for subtotal 
resection, both of which were significant increases in survival compared to 6.6 months for 
patients with biopsy only10. 
Increased survival with resection holds true even for the elderly. A study by Vuorienen, 
focusing specifically on elderly patients over the age of 65 showed median survival of 5.7 
months with open craniotomy and surgical resection compared to 2.8 months with 
stereotactic biopsy alone for an increased estimated survival time of 2.7 times longer in the 
resection group11. However, this increased survival time is modest in this patient population 
providing only a 2-3 month survival benefit.  The role of aggressive surgical management in 
the elderly population is still a controversial subject. Chronological age however, is not 
necessarily the most important factor to consider in deciding to pursue an aggressive 
surgical course. Rather biological age which takes into account the patients general health 
and functional level should be used as a guideline. 
A recent review article from 2008 examined over thirty published articles from the 
neurosurgical and neuro-oncologic literature regarding extent of resection and the effects on 
survival for malignant glioma. Only one study failed to support the idea that extent of 
surgical resection correlates with an increased survival advantage12. These authors 
recommend that based on the current prospective and retrospective data that for newly 
diagnosed malignant glioma in adults, maximal cytoreductive surgery should be 
undertaken provided that postoperative neurological deficits are minimized. 
Studies have also been performed in order to quantify exactly what percent of tumor 
resection is necessary to provide maximal survival benefit. The original landmark study was 
published in 2001 by Lacroix and colleagues in which they performed a retrospective 
analysis of 416 patients with glioblastoma treated with surgical resection13. Patients who 
received resection of greater than 98% had a mean survival of 13 months compared to 
patients receiving resection of less than 98% with mean survival of 8.8 months. 
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A more recent 2011 retrospective study by Sanai and colleagues also quantified the percent 
of tumor resection required for maximal survival benefit14. 500 patients with gliobastoma 
were treated with surgical resection followed by standard radiation and chemotherapy.  
They found a survival benefit with extent of surgical resection of as low as 78%. However, 
for maximal survival benefit, resection of greater than 95% was observed 
Overall, these studies demonstrate that prolonged survival time correlates with the extent of 
surgical resection. The data also suggests that for high grade lesions, resection of greater 
than 95% of the tumor volume should be performed in order to provide the maximal 
survival benefit. In some cases, however, such a high level of resection is unable to be 
obtained. This is usually due to tumor involvement in areas of eloquent brain tissue (areas 
involved with speech production, motor function and sensory perception), and is associated 
with a high risk of postoperative deficits. Maximizing the extent of tumor resection while 
preserving normal brain function and optimizing quality of life postoperatively represents a 
major challenge in neurosurgery. Several strategies and innovative techniques have been 
developed to assist the surgeon in safely resecting tumors located in these eloquent areas, 
particularly in the areas of neuroimaging, neuronavigation, functional mapping, and 
photodynamics. Theses new developments provide for greater resection volumes and better 
survival rates. 
3. Neuronavigation 
Image guided neuronavigation utilizes the principle of stereotaxis. The brain is considered 
as a geometric volume which can be divided by three imaginary intersecting spatial planes 
based on a Cartesian coordinate system. Any point within the brain can be specified by 
measuring its distance along these three planes. This provides a precise surgical guidance by 
referencing this coordinate system of the brain with a parallel coordinate system of the 
three-dimensional image data of the patient that is displayed on a computer-workstation so 
that the medical images become point-to-point maps of the corresponding actual locations 
within the brain15. Neuronavigation provides intraoperative orientation to the surgeon, 
helps in planning a precise surgical approach to the targeted lesion and defines the 
surrounding neurovascular structures. Conventional neuronavigation typically utilizes a 
preoperative MRI which is registered to the patients skull at the beginning of the procedure 
and is used throughout the case without any update in imaging or reregistration of the 
imaging to the corresponding brain tissue. Conventional neuronavigation is readily 
available at most centers providing neurosurgical care and is not particularly cost 
prohibitive. (Figure 1) 
Intraoperative MRI (iMRI) guided intracranial surgery improves upon the benefits of 
conventional stereotactic guided neurosurgery by providing a real time updated view of the 
anatomic relationship between tumor and normal brain structures. During surgical resection 
utilizing traditional cranial neuronavigation, the brain parenchyma becomes distorted due 
to changes in tumor volume, edema and volume of cerebrospinal fluid resulting in brain 
shift, which is not reflected in the preoperatively obtained MRI. This results in less reliability 
of the stereotactic guidance as the surgery progresses. Intraoperatively obtained MRI allows 
updating of the images used for neuronavigation as well as updated visualization of the 
contrast enhancing tissue that remains.   
www.intechopen.com




Fig. 1. Neuronavigation. Operating room setup with patient positioned and 
neuronavigational stereotactic equipment (A).  Neuronavigational MRI for stereotactic 
guided biopsy showing a temporal lobe glioma in three planes. 
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Over the past decade several studies have looked at iMRI guided resection vs conventional 
neuronavigation in patients with glioma. In 2000, Wirtz and colleagues examined 68 cases of 
high grade glioma resected with iMRI16. Of the 68 cases, 27% of showed GTR on the first 
iMRI scan and 66% percent underwent continued resection. Median survival was 13.3 
months for GTR vs 9.2 months for subtotal resection. 
In 2005, Hisrschberg and colleagues examined the use of iMRI in 32 patients with 
glioblastoma compared to a matched control group of 32 patients using conventional 
neuronavigation. They found a mean survival time of 14.5 months in the iMRI group vs 12.1 
months in the control group. They also saw a significant increase in length of surgical time 
with iMRI 5.1 hours vs 3.4 with conventional navigation. They also reported postoperative 
functional performance results, which were not significantly different between the two 
groups. Neurologic improvement was seen in 16% of patients, 55% showed no change, and 
19% showed some worsening of symptoms. 
In 2010, Senft and colleagues reported on 41 patients with glioblastoma, 10 of whom 
underwent resection with iMRI and 31 who received resection by conventional means17.  
GTR was seen in all 10 iMRI cases and 19 of the conventional group. Median survival was 88 
weeks for the iMRI group and 68 weeks for the conventional group. Median survival in 
regards to the extent of resection was 74 weeks for the 29 patients who obtained GTR vs 46 
weeks for the 12 patients who obtained subtotal resection. 
A recent 2011 review article of 12 studies from the current literature examined the benefits 
of iMRI vs conventional stereotactic surgery for glioblastoma. The authors concluded that 
iMRI guided surgery is more effective that conventional neuronavigational surgery in 
increasing the extent of resection and prolonging survival in patients with glioblastoma18. 
However there are currently no randomized trials with validated endpoints that 
demonstrate the additional value of iMRI guided surgery.  Intraoperative MRI is currently 
of limited availability, adds significant expense and prolongs surgical time. Therefore, the 
decision to use this modality should be made judiciously on a case by case basis. 
These systems are not perfect and continued improvements are needed. Advances in real 
time surgical imaging are important to reduce the neuronavigational inaccuracies due to 
brain shift as well as to provide a clearer more accurate representation of the tumor margins 
throughout the case. Currently these systems still rely heavily on a rigid fixation of the 
patient’s head and a registration landmark. Movement of the patient’s head, pin slippage, 
and loss of registration can drastically limit the utility of these surgical tools and more 
robust technologies are needed.  Despite these limitations, the use of improved 
neuroimaging and newer methods of neuronavigation can significantly improve the extent 
of resection and thereby increase the survival rates for patients with glioma. 
4. Functional mapping    
Functional mapping is another tool that is changing the surgical management of glioma 
therapy. These new techniques allow the protection of eloquent areas of the brain while 
permitting the extent of surgical resection to be maximized. With this technology, lesions 
that were previously thought to be inoperable due to location are now often resectable.  One 
such procedure is awake craniotomy. Intraoperative direct electrostimulation under awake 
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anesthesia is the best technique to locate eloquent domains as well as to distinguish 
functional area from nonfunctional area.  In 2008, Duffau and colleagues, reported the 
largest experience with cortical and subcortical mapping of gliomas affecting the language 
area19. They performed resection using awake craniotomy and direct electrical stimulation 
in 115 patients. 98% of patients improved or returned to their preoperative baseline 
following resection guided by direct electrostimulation.  Awake craniotomy however 
presents several challenges in regards to anesthesia, patient comfort and anxiety as well as 
prolongation of operative time.  
Functional magnetic resonance imaging (fMRI) is another improving technology that shows 
promise for increasing the extent of surgical resection while minimizing neurological 
deficits by providing functional mapping with the use of newly developed imaging 
modalities. The use of functional magnetic resonance imaging (fMRI) allows information 
regarding the location of specific brain functions such as speech, motor function, and 
sensory perception to be mapped to three-dimensional reconstructed MRI images. Blood 
oxygen level dependent (BOLD) fMRI is one of the most commonly used forms of fMRI. 
BOLD fMRI provides functional information based on cerebral hemodynamic responses by 
measuring changes in the ratio of blood oxyhemoglobin and deoxyhemoglobin during the 
presentation of a various stimuli to the patient. This data can then be used to map task-
driven regional cortical activity in patients to noninvasively locate the brains essential 
eloquent areas and guide surgical planning. (Figure 2) 
In 2010, Talacchi and colleges retrospectively examined the use of preoperative fMRI and 
neuronavigation compared to traditional intraoperative neurostimulation in 171 patients20.  
They found that preoperative fMRI provided equivalent rate of GTR when compared to the 
invasive neurostimulation 71% vs 73%c compared to 40% in resections not utilizing either 
modality.  Similar findings have been demonstrated by additional authors21,22. Together 
these studies support fMRI as a viable alternative to awake craniotomy and functional 
neurostimulation with the benefit of reduced operative time as well as elimination of the 
challenges associated with awake craniotomy. 
Diffusion tensor imaging (DTI) is an additional form of functional magnetic resonance 
imaging used to delineate white matter anatomy. DTI is based upon the principle that water 
preferentially diffuses along the long axis of white matter tracts and the degree and 
direction of water diffusion can be measured. Tractography uses algorithms to process this 
data and to reconstruct three-dimensional maps representing subcortical fiber tracts23. 
Tractography can be used in surgical planning to show the relationship between white 
matter tracts and tumor. It can reveal whether tracts are displaced, disrupted, or infiltrated 
by tumor. (Figure 3) 
In 2007, Wu and colleges reported a large prospective randomized controlled trial of 238 
patients with gliomas24. A randomized study group of 118 patients underwent resection 
with DTI tractography and neuronavigation while a control group of 120 patients 
underwent resection with neuronavigation alone. They found a significant increase in the 
ability to achieve GTR with the use of DTI tractography with 74.4 % of patients in the study 
group achieving GTR compared to 33.3% of patients in the control group.  This translated 
into an increased mean survival time 21.2 months in the study group compared to 14.0 
months mean survival in the control group. They also found better outcomes with DTI 
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tractography with motor strength deterioration occurring in 15.3% of patients in the study 
group compared to 32.8% in the control group. Improved outcome was also demonstrated 
in 6 month Karnofsky Performace Scale scores with a mean score of 77 for study group 
patients and 53 for the control group. When combined, fMRI, neuronavigation, and DTI 
allows precise surgical resection of the maximal tumor volume while sparing intact fiber 
tracts as well as eloquent areas of the brain. This results increased patient survival and 






Fig. 2. Functional MRI. MRI generated from BOLD data in a patient with large frontal lobe 
glioma showing areas of activation during a sentence completion task.  
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Fig. 3. Tractography.  3-Dimensional reconstruction showing fiber tracts generated from DTI 
MRI sequence in a patient with large glioblastoma multiforme.  
5. Florescence guided resection 
Another problem arises in surgery when dealing with the infiltrating malignant cells present 
at the tumor margins. These cells often lie outside the area of enhancement on neuroimaging 
and intraoperatively appear grossly and microscopically indistinguishable from normal 
brain tissue. These areas of infiltrating cells contribute to reoccurrence and negatively effect 
long-term tumor control if not resected. 
Fluorescence image guided surgical resection (FIGS) is another innovative surgical 
technique which uses fluorescence intraoperatively to enhance the visualization of abnormal 
tumor cells intraoperatively and allow for maximal extent of resection. 5-Aminolevulinic 
acid (ALA) is injected systemically prior to surgery. High grade gliomas and other 
metabolically active tumors take up ALA at a rapid rate.  After gross resection of the visible 
tumor, a specially filtered blue light can illuminate the areas of high uptake within the 
cavity allowing selective resection of the residual areas25.  
In  2000, Stummer and colleagues reported an initial study of the efficacy of FIGS which  
demonstrated FIGS to be quite specific (only 0.4 % of fluorescent biopsy sites did not contain 
tumor cells) and quite sensitive (81.6% of fluorescent biopsy sites contained tumor cells)26. In 
2006 this same author reported a multicenter phase III trial comparing FIGS to placebo and 
found 64% complete surgical excision with fluorescence guided resection compared to 38% 
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complete excision in the placebo group27. In 2007 Stepp and colleagues reported similar 
findings with GTR in 65% of patients undergoing FIGS compared to 36% in placebo group28. 
They also demonstrated improved 6 month progression free survival in 41% of patients in 
the study group vs 21% in the control group. 
Despite the positive initial results with FIGS, there are several limitations of this modality. 
The blue light used to illuminate 5-ALA has a depth of penetration of only a few millimeters 
and is easily obscured by blood products. Also 5-ALA has minimal uptake in tumors that 
have minimal contrast enhancement or that do not enhance at all, such as low grade 
glioma29,30.  Advances in florescence guidance, particularly in its use for resection of these 
low grade, non-enhancing lesions are needed. As this technology continues to progress it 
will allow for greater extent of resection and increased survival in patients with glioma.  
6. Photodynamic treatment    
Photodynamic treatment (PDT) is another novel surgical method for the treatment of 
malignant glioblastoma. It utilizes the selective uptake of a photosensitizer by the individual 
tumor cells followed by irradiation of the tumor with light of a specific wavelength during 
surgery, which activates the photosensitizer to destroy the tumor cells selectively via 
oxidative reactions.  Many different photosensitisers have been studied with the most 
promising being haematoporphyrin derivative (HPD). One of the greatest benefits with PDT 
is that it is a localized treatment, which lacks the systemic side effects associated with 
chemotherapy and radiation.  The major side effect associated with PTD is cerebral edema in 
the irradiated area which can usually be managed with steroids. 
In 2005, Stylli and colleagues reported one of the largest series of PDT for high grade glioma 
in 136 patients31. They utilized HPD administered IV preoperatively followed by irradiation 
with laser light during surgery. Median survival time following treatment for the 78 patients 
with glioblastoma was 14.3 months and median survival for the patients with anaplastic 
astrocytoma was 76.5 months. The same authors have also reported a review of the 
literature examining 10 studies, which show similar results although with fewer numbers of 
patients32. They conclude that PDT shows potential as a novel adjuvant therapy for glioma 
treatment along with chemotherapy and radiation therapy. However, further controlled 
clinical trials are needed to standardize HPD dosage as well as type and dose of light 
irradiation.  
7. Radiation therapy 
Following surgical resection, radiation therapy (RT) is considered the next step in the 
treatment of glioma. The principal goal of RT is to destroy residual tumor cells that were not 
removed with surgery, therefore preventing or postponing tumor reoccurrence. RT is most 
affective on smaller lesions and is therefore an adjuvant therapy in addition to surgical 
resection. Resection of maximal tumor bulk results in smaller residual volumes which are 
more responsive to RT and thereby increase the efficacy of RT.  Historically, conventional 
radiation therapy using external beam radiation has been the main modality of radiotherapy 
used for glioma. Due to the risk of radiation induced injury to normal brain tissue, 
conventional radiation therapy is fractionated and the total dose is delivered over several 
treatments. Standard therapy usually consists of a total radiation dose in the range of 50–60 
Gy administered over 20-30 fractions each with a dose of 1.8–2.0 Gy 33. 
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Novel methods of administering radiation therapy are also being developed. Following 
optimal surgical resection, image guided stereotactic radiosurgery (SRS) is now being 
evaluated for treatment these lesions. This new modality utilizes a single high doses of 
radiation specifically targeted to a well-defined lesions using detailed neuroimaging. This 
allows delivery of focused radiation to the tumor with a much lower dose to adjacent non-
targeted tissue which results in reduced side effects compared with traditional methods.  
For low grade gliomas, adjuvant RT following resection has failed to show a survival 
benefit. In cases of disease progression or inoperable lesions with neurologic symptoms, 
delayed RT appears to provide the same survival advantage as postoperative RT34. For  
newly diagnosed high grade gliomas studies have demonstrated that SRS does not provide 
a significant survival advantage over conventional radiotherapy35,36. The use of SRS has also 
been explored as a treatment for recurrent high grade lesions.  A recent article by Romanelli 
and colleagues reviewed 17 retrospective studies examining the role of SRS in the treatment 
of recurrent high grade glioma. This review demonstrated that SRS is associated with 
prolonged survival in patients with recurrent GBM with median survival times ranging 
from 7.5 to 30 months37. SRS has been shown to have no significant advantage as a first line 
radiation therapy for glioma and the results for recurrent glioma are inconclusive, therefore 
further study on the role of SRS in glioma treatment is needed.  
In addition to externally administered sources of radiation therapy, interstitial 
brachytherapy is another form of radiation therapy used to treat glioma, which refers to 
surgical placement of the radioactive source a short distance from or within the tumor being 
treated. Brachytherapy was developed due to the observation that 80% of malignant gliomas 
reoccur within 2cm of the initial tumor site following resection. By placing the radioactive 
source directly in the tumor or tumor bed, continuous high dose radiation increases damage 
to nearby proliferating tumor cells located at the margin with a rapid fall off in the dose 
delivered to normal cells which are located farther from the source. 
There are multiple surgical methods for delivering the radiation source to the tumor. During 
surgery, temporary implants can be placed which provide a source of radiation for a 
specified duration and are then removed at a later time, however this usually requires 
multiple procedures. To avoid multiple procedures, small radioactive seed have been 
developed which are surgically implanted and are left permanently to gradually decay over 
a period of weeks to months to a state of zero radiation emission.  Another novel approach 
uses a surgically implanted catheter system with an expandable balloon reservoir implanted 
at the site of resection and a catheter connecting to a subcutaneous access port. A radioactive 
solution can then be injected percutaneously into the implanted reservoir and retrieved at a 
later time. The most commonly radiation sources used for glioma brachytherapy are iodine-
125 and iridium-192. 
Brachytherapy is usually reserved for cases of high grade gliomas which have shown 
reoccurrence since several studies have shown no significant survival benefit for 
brachytherapy in newly diagnosed glioma38,39. One large randomized study by Selker and 
colleagues with 270 patients examined the use of interstitial brachytherapy in newly 
diagnosed high grade glioma40. Patients were randomized to two groups, one receiving 
resection, external beam radiation, and chemotherapy with the other group receiving 
resection, external beam radiation, chemotherapy, and 125I permanent interstitial 
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brachytherapy. They found no statistical difference in the median survival time between the 
two groups for newly diagnosed high grade glioma. 
The results for brachytherapy in the case of recurrent high grade glioma appear to show 
improved survival41–43. One large study with 95 patients by Gabayan and colleagues 
examined the use of the GliaSite Radiation Therapy System in the treatment of recurrent 
high grade glioma. This system utilizes 125I administered via a surgically implanted balloon 
catheter system. All patient were initially treated with resection followed by external beam 
radiation. Following reoccurrence, patients underwent maximal surgical debulking 
followed by implantation of an expandable balloon catheter system. Radioactive solution 
was then administered between 2-6 weeks following the debulking procedure. Patient 
undergoing this treatment showed median survival of 36.3 weeks from the time of the 
debulking surgery with a 1 year survival of 31.1%. Although no control group was used in 
this study, survival times were compared to matched patients from another published study 
matched for age, KPS, and surgical management. These control patients showed a median 
survival of 23 weeks following resection for reoccurrence. The results from the 
brachytherapy group compare favorably with the control group.  Further studies including 
randomized trials are still needed but brachytherapy appears to show promise as adjuvant 
therapy in recurrent glioma. 
8. Chemotherapy 
In addition to surgical resection and radiation therapy the other mainstay of treatment for 
malignant glioma is chemotherapeutics. Chemotherapy is another adjuvant therapy to be 
utilized along with surgical resection. As with radiation therapy, chemotherapy is more 
effective in treating smaller tumor volumes and therefore maximizing the extent of surgical 
resection is important in order to provide a more favorable response to chemotherapy44. 
Two main classes of drugs are currently used, alkylating agents (carmusitine, 
temozolomide) and antiangiogenic agents (bevacizumab). 
9. Blood brain barrier 
The blood brain barrier (BBB) presents difficulty in the chemotherapuetic treatment of 
gliomas as many agents that are effective for the treatment of systemic disease are unable to 
cross the BBB. There have been several developments designed to open the BBB and provide 
direct treatment of the central nervous system. Initial therapies to open the BBB made use of 
small lipophilic molecule drugs administered systemically for increased permeation across 
the BBB. This approach was limited by drug binding to plasma protein as well as 
extravasation of the drug back across the BBB into the systemic circulation. Other early 
treatments used osmotic modification of the BBB with agents such as mannitol given intra-
arterially to disrupt the BBB followed by the chemotherapeutic agent of choice.  The 
effectiveness of these early methods were limited due to the transient elevation of drug 
concentration within the brain tissues and short drug half–life which did not allow for 
accumulation of the drug at a therapeutic concentration.  Over the past decade, several 
innovative surgical methods of opening the BBB have been developed to provide longer 
acting and direct treatment to the tumor cells. 
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10. Implantable polymers 
One advancement has come in the area of surgically implantable polymers, which are 
infused with chemotherapeutic agents. These polymers are then placed into the surgical 
cavity following resection to provide direct application of the chemotherapeutic agent to the 
tumor bed over a prolonged period of time as the polymer degrades and releases the agent. 
The most widely studied therapy of this nature utilizes a polyanhydride wafer embedded 
with carmustine (gliadel wafers). Gliadel is currently the only interstitial chemotherapy 
treatment approved for use with malignant glioma. Wafers can be implanted at the time of 
initial surgery or reserved for episodes of reoccurrence. Several trials have demonstrated 
increased survival following the use of implantable wafers.  For initial tumor treatment, 
increased survival has been shown of 13.9 months compared to 11.6 months in non-
treatment group. Wafer usage for treatment of tumor reoccurrence provided increased 
survival of 31 weeks compared to 23 weeks in non-treated patients45–47.   
Overall, these studies show a 35% risk reduction of death with the use of gliadel, with a 
median survival of 14 months, which is a 2.5 month improvement over placebo. 1 year 
survival is approximately 10% better with use of gliadel48.  Care must be taken with the use 
of this therapy as side effects of necrosis, cerebral edema, and seizure are common but can 
be controlled with steroid and antiepliptic therapy.  
Use of gliadel can also exclude from further clinical trials and newer treatments. It can cause 
confounding effects on another trial because all of these are so new.  Improvement of 
surgical resection can eliminate these problems. 
11. Nanoparticles 
Another novel approach still in the early phases of development is the use of surgically 
implantable nanoparticles to deliver chemotherapeutic agents. Small spherical particles 7 to 
10 nanometers in size comprised of polymers or liposomes are non-covalently attached to 
slow sustained release formulations of chemotherapeutic drugs for delivery. These 
nanoparticles are small enough to cross the blood brain tumor barrier (BBTB) and transmit 
drug directly into individual tumor cells49.  
Nanoparticles can be administered intravascularly or directly into the brain via a surgically 
implanted catheter. Delivery of nanoparticles via surgically implanted catheter has the 
benefit of greater volume of distribution directly to the brain tissue compared with diffusion 
alone50. Development of these nanoparticle systems for treatment of malignant brain tumors 
is currently in the animal model phase and no human studies are currently available. Rat 
models of glioblastoma have shown increased survival using doxorubicin bonded to 
cyanoacrylate nanoparticles for delivery to tumor cells. The drug transport across the BBB 
by nanoparticles appears to be due to a receptor-mediated interaction with the brain 
capillary endothelial cells, which is facilitated by certain plasma apolipoproteins adsorbed 
by nanoparticles in the blood.  Nanoparticle uptake appears selective to tumor cells in these 
models as the animals did not manifest signs of neurotoicity51.  
In addition to drug delivery, nanoparticles are being investigated for use in neuroimaging. 
Current imaging techniques have a maximum resolution of 1 mm. Nanoparticles could 
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improve the resolution by a factor of ten or more, allowing detection of smaller tumors and 
more precise surgical resection. Several nanoparticle-based contrast materials have been 
used to enhance MRI imaging. One iron oxide nanoparticle currently under study has 
shown an innocuous toxicity profile as well as sustained retention in mouse tumors52. These 
fluorescent nanoparticles improved the contrast between the tumor tissue and the normal 
tissue in both MRI and optical imaging, which can be used during surgery to see the tumor 
boundary more precisely. 
Another promising role of nanoparticle in the treatment of glioma involves hyperthermia 
treatment. The heating of cancerous tissues between 41 and 45°C, has been shown to 
improve the efficacy of cancer therapy when used in conjunction with chemotherapy and 
radiation52. Magnetic nanocomposites based on iron oxide can be used as implantable 
biomaterials for thermal cancer therapy applications at the time of surgery. These implanted 
particles can then be remotely heated by exposure to an external alternating magnetic field.  
In 2011, Maier-Hauff and colleagues reported a trial of magnetic nanoparticle thermotherapy 
in conjunction with radiation treatments in 59 patients with recurrent glioblastoma53. Magnetic 
fluid was instilled within the tumor site using a neuronavigational procedure comparable to a 
brain needle biopsy and an external magnetic field was then applied for multiple treatments.  
Patients undergoing this procedure showed a mean survival time of 13.4 months after the first 
re-occurrence. Thermotherapy using magnetic nanoparticles in conjunction with a reduced 
radiation dose is safe and effective and leads to longer overall survival compared with 
conventional therapies in the treatment of recurrent GBM. 
12. Immunotherapies 
Using the body’s  own immune system to fight glioma, immunotherapy, is a new field 
which has seen significant advancements over the past decade.  There are two categories of 
immunotherapy for glioma that are currently undergoing clinical research. Passive 
immunotherapy involves the activation of cytotoxic effector cells ex vivo and thee transfer of 
these activated cells back into the patient’s body. Active immunotherapy, on the other hand, 
uses an exogenous trigger which causes activation of endogenous effector cells within the 
patients own body to target tumor cells. Active immunotherapy is generally employed in 
the tumor vaccine model. Surgery plays a large role in these therapies, as sizeable volumes 
of tumor tissue must be surgically obtained in order to construct the immunotherapeutic 
agents. Also several of these therapies utilize direct delivery of these agents into the brain 
during surgery. 
Current clinical trials utilizing passive immunotherapy focus on the activation of effector 
cytotoxic T lymphocytes, natural killer cells, or lymphokine activated killer cells sensitized 
to glioma-associated antigens. Once such trial for glioblastoma treatment uses donor 
cytotoxic T lymphoyctes which are sensitized ex vivo to recognize patient human leukocyte 
antigen (HLA) groups expressed on the surface of glioma cells but not on normal neurons or 
glia.  After surgical resection, the sensitized CTL cells are placed in the resection cavity as 
well as surgical placement of an intraparanchemal catheter and reservoir system to allow 
future delivery of CTL cells. An initial pilot study with this model showed significant 
survival benefit in 3 of 6 patients with 2 patients surviving >15 years since beginning 
immunotherapy54. 
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Treatments using active immunotherapy via cell-based and peptide vaccines are also under 
study. Cells from glioma tumors are thought to be poor antigen-presenting cells because 
they often secrete immunosuppressive cytokines as well as  growth factors such as 
transforming growth factor and vascular endothelial growth factor which can have a 
negative effect on T cell and natural killer cell activity. Tumor vaccines are designed to 
augment tumor-specific cellular immunity and enhance low-level immunity by stimulating 
the production of higher-avidity T cells specific to a tumor55. 
Chang and colleagues published results from one vaccine based phase II clinical trial in 
2011. 16 patients with glioblastoma (8 newly diagnosed, 8 recurrent) underwent craniotomy 
for maximal cytoreduction followed by standard external beam radiation therapy in the 
newly diagnosed patients.  Tumor cells obtained from the surgical resection were cultured 
in the laboratory and combined with autologous dendritic cells to produce vaccine. The 
vaccine was administered to patients via subcutaneous injection over lymph nodes for a 
total of 10 treatments over a 6 month period. Median survival and 5 year survival was 381 
days and 12.5% for the newly diagnosed group, 966 days and 25% for the recurrent group 
compared to 380 days mean survival and 0% five years survival for a 16 patient age and sex 
matched historical control group. 
Although most published results are from preliminary studies with small numbers of 
patients, immunotherapy for the treatment of glioma is a promising area currently 
undergoing multiple phase II and phase III trials for FDA approval54.  Once the basic 
efficacy of these initial studies have been verified as a plausible modality for the treatment 
of glioma, randomized and controlled clinical trials can be undertaken to further explore the 
full potential of this therapy. 
13. Gene therapy 
Gene therapy is another novel modality used in the treatment of glioma, which focuses on 
the delivery of apoptotic genes at the time of surgical intervention and implantation in the 
surgical cavity. One of the most effective methods of in vivo gene delivery is the use of viral 
vectors as gene carriers. Retroviruses, adenovirus, and herpes simplex virus-1 (HSV-1) are 
all currently undergoing trials as vectors for viral brain tumor therapy Replication 
competent retroviruses have been shown to have infection rates of 97% with specificity for 
tumor cells without significant effects on non-tumor cells56. Adenovirus and HSV-1 are used 
in both replication competent and replication defective forms and have shown high 
transgenic capacity and persistent gene expression57.  
In 2003, Germano and colleagues reported a series of 11 patients with high grade glioma 
treated with gene therapy using adenovirus as a viral vector57. Adenovirus was used to 
transfer the herpes simplex-thymidine kinase gene into malignant glioma cells. This gene 
then phosphorylates ganciclovir, a non-cytotoxic nucleotide analog, into a compound that 
halts the transcription of DNA in dividing cells. Since normal brain cells are not rapidly 
dividing they are not affected. At the time of surgery, following gross total resection, the 
viral solution was injected directly into the tumor bed. This was followed by administration 
of ganciclovir systemically over 7 days.  Of the 11 patients 10 had a survival of > 52 weeks 
following treatment. This survival time was associated with maintaining quality of life. 8 
patients maintained a KPS of greater than 70 after 3 months and 5 patients 6 months after 
treatment. 
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Oncolytic viruses are also currently being used for clinical trials. These virus replicate 
selectively within tumor cells and can lead to increased intratumoral viral titers and cell 
death58. In 2004, Harrow and colleges used a modified herpes simplex virus with an affinity 
for glioblastoma cells which replicates only in rapidly diving cells causing cell lysis while 
sparing normal terminally differentiated cells.  Twelve patients, 6 with newly diagnosed 
glioblastoma and 6 with recurrent glioblastoma, underwent craniotomy and surgical 
resection. Following resection during the same surgical procedure they were injected with 
the modified herpes virus at 8-10 sights adjacent to the tumor bed. Four patients, 2 newly 
diagnosed and 2 with recurrent disease showed survival of greater than 15 months 
following treatment. 
Viral vectors, although promising, do have several limitations. Viral vectors suffer from low 
levels of gene incorporation due to limited diffusion into the brain parenchyma as well as 
low transfection rates of some cell types. Formation of antigenicity to vectors and 
introduced gene products causes additional difficulties. Also the use of retroviruses that 
incorporate genes into the host chromosome can result in insertional mutagenesis and 
propensity to form new tumors. The use of genetically modified cells to deliver gene 
therapy to the CNS may avoid some of these limitations. The use of stem cells is one area of 
research being used to avoid these limitations seen with traditional gene therapy. 
Neural stem cells (NSC) are self-renewing multipotent cells found in the fetal brain within 
the ventricular zone, midbrain and spinal cord.  These cells have the ability to repopulate a 
degenerated CNS region and can migrate toward pathologically altered tissues, including 
stroke, trauma and tumors. Genetic changes in NSCs may result in tumorigenesis by 
activation of oncogenes and/or inactivation of tumor suppressor genes. 
Within brain tumors, a population of cells known brain tumor stem cells (BTSC) have been 
found.  They are resistant to current treatments and capable of maintaining and propagating 
these tumors59. BTSCs are thought to arise from aberrant NSCs or from mature cells that 
have undergone mutation and dedifferentiation. BTSCs are similar to normal stem cells with 
regards to self-renewal, capacity, multi-potentiality, tumorigenicity as well as migratory 
capability. Transformation of these neural stem cells and their progenitor cells may therefore 
lead to the formation of BTSCs and eventually malignancy60. Gene therapies focusing on 
preventing the malignant transformation of 
NSCs into BTSCs as well as the use of normal stem cells as a method of targeted delivery of 
therapeutic agents to glioma cells are currently under investigation. 
Genetic modification of NSCs to secrete anti-tumor agents allows targeted delivery as well 
as provides a high level of active compounds at the local site of neoplasm. These types of 
therapies are still in the early stages and have not been evaluated in human glioma patients, 
however there are studies which have shown good results using animal models.  One model 
using neural stem cells modified to produce high quantities of interleukin-4 in vivo was 
examined in Spraque-Dawley rats61. They implanted the modified NSCs into the brain tissue 
of rats affected with malignant gliobastoma and found a long term survival of 50% 
compared to control animals.  
Another rat study used immortalized neural progenitor stem cells to express a eukaryotic 
catalytic enzyme that converts the nontoxic compound 5-flourocytosine into the highly toxic 
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drug 5-flourouracil62. These stem cells were then implanted in rats with induced 
glioblastoma and the animals were subsequently treated with the nontoxic compound. After 
10 days, the animals treated with the modified NSCs showed significant 50% decrease in 
tumoral mass compared to a control group. After histopathological examination of the 
treated tissue, they also found high levels of the toxic 5-flourouracil drug in adjacent tissue 
demonstrating in vivo conversion of the nontoxic compound to the toxic drug with 
therapeutic benefit.  
Neural stem cells are also being used as vehicles for the tracking and suppression of 
glioblastoma. These methods exploit the tendency of NSCs to preferentially migrate towards 
brain tumors. This allows NSCs to be labeled and used as diagnostic imaging tools to 
identify extent of tumor invasion. One such animal model used NSCs modified to express 
the firefly luciferase gene63. These cells were then implanted into the contralateral brain 
parenchyma as well as injected into the ventricles of mice with intracranial gliomas. Over a 
period of 3 weeks, serial bioluminescence imaging was performed, which showed migration 
of the implanted cell across the corpus callosum with a maximal density at the site of the 
tumors. A subsequent study using the same model but with the addition of an apoptosis-
promoting gene to the NSCs was performed to evaluate the therapeutic possibilities of this 
model. NSCs were modified not only to express the luciferase gene but also the tumor 
necrosis factor related apoptosis inducing ligand S-TRAIL. The transformed NSCs were then 
stereotactically implanted into the left frontal lobe of mice and glioma cells were 
stereotactically injected into the right frontal lobe of the same animals. Serial imaging was 
again performed which initially showed increased tumor volumes at the site of glioma 
injection as well as migration of the NSCs towards the tumor areas. After 16 days however 
there was a considerable decrease in tumor growth and a significant reduction in tumor cells 
on quantitative analysis compared to control animals. They also found expression of the S-
TRAIL gene product at the tumor site on histopathological examination. These studies 
demonstrate the promising role that stem cells can play in the treatment of glioma. 
14. Conclusion 
Surgical resection remains the single most important primary treatment in the management 
of patients with glioma and extent of surgical resection directly correlates with increased 
patient survival. In this chapter we reviewed several innovative technologies and surgical 
methods for increasing the extent of resection as well as several adjuvant therapies and the 
important role that surgery plays in maximizing the potential benefit of these therapies in 
the treatment of glioma. As our ability to increase the extent of resection improves and new 
innovative technologies are perfected, we will continue to see improvements in long term 
survival in patients affected with glioma. 
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